Capricor Therapeutics ( (CAPR) ) has shared an update.
Capricor Therapeutics has announced a substantial public offering of 4,412,000 shares of common stock priced at $17.00 per share, with an option for underwriters to purchase an additional 661,800 shares. Expected to raise approximately $75 million, the funds will fuel the advancement of Capricor’s innovative cell and exosome-based therapies, particularly focusing on the development of its lead product, deramiocel, targeting rare diseases like Duchenne muscular dystrophy. This strategic financial move underscores Capricor’s commitment to transforming treatment landscapes and expanding its clinical development efforts.
See more insights into CAPR stock on TipRanks’ Stock Analysis page.
